NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,592.38 mln
Float29.10 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
69.09
Transformational upside
Relative Strength
89
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-29.60
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
MBX Biosciences is a drug development company based in Carmel, Indiana, working on targeted hormone-based treatments for conditions affecting the endocrine and metabolic systems. Its furthest-along treatment, Canvuparatide, is currently in a Phase 3 trial for a rare condition where the parathyroid glands do not produce enough hormone, while a second drug, Imapextide, is in Phase 2 testing as a potential solution for dangerous blood sugar drops that can occur after weight-loss surgery. The company is also in early-stage work on a third treatment aimed at obesity and related health conditions. Founded in 2018, MBX is building a focused pipeline around precision therapies designed to address gaps in hormonal and metabolic care.
